In vitro and in vivo activity of a killer peptide against Malassezia pachydermatis causing otitis in dogs

Medical Mycology

Volumn 52, Issue 4, 2014, Pages 350-355

  Cafarchia, Claudia ^a   Immediato, Davide ^a   Di Paola, Giancarlo ^a   Magliani, Walter ^b   Ciociola, Tecla ^b   Conti, Stefania ^b   Otranto, Domenico ^a   Polonelli, Luciano ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Dogs; Killer peptide; Malassezia pachydermatis; Otitis; Therapy

Indexed keywords

KILLER DECAPEPTIDE; POLYPEPTIDE; UNCLASSIFIED DRUG; PEPTIDE; ANTIFUNGAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOG; ERYTHEMA; EXTERNAL OTITIS; FUNGICIDAL ACTIVITY; HYPERPIGMENTATION; LICHENOID ERUPTION; MALASSEZIA PACHYDERMATIS; NONHUMAN; POPULATION SIZE; PRURITUS; YEAST; YEAST CELL; CELL COUNT; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; ADVERSE DRUG REACTION; ANIMAL; BACTERIAL COUNT; CLINICAL TRIAL; DERMATOMYCOSIS; DRUG EFFECTS; FEMALE; ISOLATION AND PURIFICATION; MALASSEZIA; MALE; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; OTITIS; PATHOLOGY; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VETERINARY;

CANIS FAMILIARIS; MALASSEZIA PACHYDERMATIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLONY COUNT, MICROBIAL; DERMATOMYCOSES; DOGS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALASSEZIA; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OTITIS; TREATMENT OUTCOME;

EID: 84902973835     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myt016     Document Type: Article

References (23)

1. Cafarchia C, Dell'Aquila ME, Capelli G, Minoia P, Otranto D. Role of beta-endorphin on phospholipase production in Malassezia pachydermatis in dogs: new insights into the pathogenesis of this yeast. Med Mycol 2001; 45: 11-15.
2. Cafarchia C, Otranto D. Association between phospholipase production by Malassezia pachydermatis and skin lesions. J Clin Microbiol 2004; 4: 4868-4869.
3. Guillot J, Bond R. Malassezia pachydermatis: a review. Med Mycol. 1999; 37: 295-306.
4. Batra R, Boekhout T, Guého E et al. Malassezia Baillon, emerging clinical yeasts. FEMS Yeast Res 2005; 5: 1101-1113.
5. Chryssanthou E, Broberger U, Pettini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr 2001; 90: 323-327.
6. Bond R. Superficial veterinary mycoses. Clin Dermatol 2010; 28: 226-236.
7. Negre A, Bensignor E, Guillot J. Evidence-based veterinary dermatology: a systematic review of interventions for Malassezia dermatitis in dogs. Vet Dermatol 2009; 20: 1-12.
8. Cafarchia C, Figueredo LA, Iatta R, Montagna MT, Otranto D. In vitro antifungal susceptibility of Malassezia pachydermatis from dogs with and without skin lesions. Vet Microbiol 2012; 155: 395-402.
9. Morris DO. Malassezia dermatitis and otitis. Vet Clin North Am Small Anim Pract 1999; 29: 1303-1310.
10. Nijima M, Kano R, Nagata M, Hasegawa A, Kamata H. An azole-resistant isolate of Malassezia pachydermatis. Vet Microbiol 2011; 149: 288-290.
11. Hensel P, Austel M, Wooley RE, Keys D, Ritchie BW. In vitro and in vivo evaluation of a potentiated miconazole aural solution in chronic Malassezia otitis externa in dogs. Vet Dermatol 2009; 20: 429-434.
12. Magliani W, Conti S, Ciociola T et al. Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs. Future Med Chem 2011; 3: 1209-1231.
13. Polonelli L, Magliani W, Conti S et al. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 2003; 71: 6205-6212.
14. Olivry T, Marsella R, Iwasaki T et al. Validation of CADESI- 03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. Vet Dermatol 2007; 18: 78-86.
15. Cafarchia C,Gallo S, Capelli G, OtrantoD.Occurrence and population size of Malassezia spp. in the external ear canal of dogs and cats both healthy and with otitis. Mycopathologia 2005; 160: 143-149.
16. Cafarchia C, Gallo S, Romito D et al. Frequency, body distribution, and population size of Malassezia species in healthy dogs and in dogs with localized cutaneous lesions. J Vet Diagn Invest 2005; 17: 316-322.
17. Cafarchia C, Gasser RB, Figueredo LA, Latrofa MS, Otranto D. Advances in the identification of Malassezia. Mol Cell Probes 2011; 25: 1-7.
18. Polonelli L, Ciociola T, MaglianiWet al. Peptides of the constant region of antibodies display fungicidal activity. PLoS One 2012; 7: e34105.
19. Morris DO. Malassezia dermatitis and otitis. Vet Clin North Am Small Anim Pract 1999; 29: 1303-1310.
20. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25: 106-141.
21. Peano A, Gallo MG.Management of Malassezia-related diseases in the dog. Parassitologia 2008; 50: 85-88.
22. Masuda A, Sukegawa T, Tani H et al. Attachment of Malassezia pachydermatis to the ear dermal cells in canine otitis externa. J Vet Med Sci 2001; 63: 667-669.
23. Morris DO, DeBoer DJ. Evaluation of serum obtained from atopic dogs with dermatitis attributable to Malassezia pachydermatis for passive transfer of immediate hypersensitivity to that organism. Am J Vet Res 2003; 64: 262-266.